Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Smirnova E, et al. Among authors: myers rp. Hepatology. 2022 Dec;76(6):1811-1824. doi: 10.1002/hep.32568. Epub 2022 Jun 23. Hepatology. 2022. PMID: 35561146 Free PMC article.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. Trauner M, et al. Among authors: myers rp. Hepatology. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509. Epub 2019 Mar 10. Hepatology. 2019. PMID: 30661255 Free PMC article. Clinical Trial.
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin AN, Myers RP, Goodman Z, Landi A, Houghton M, Green RM, Levy C, Kowdley KV, Bowlus CL, Muir AJ, Trauner M. Gindin Y, et al. Among authors: myers rp. Hepatology. 2021 Mar;73(3):1105-1116. doi: 10.1002/hep.31488. Epub 2021 Feb 28. Hepatology. 2021. PMID: 32745270 Free PMC article.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; for the ATLAS Investigators. Loomba R, et al. Among authors: myers rp. Hepatology. 2021 Feb;73(2):625-643. doi: 10.1002/hep.31622. Hepatology. 2021. PMID: 33169409 Clinical Trial.
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Sanyal AJ, et al. Among authors: myers rp. Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7. Hepatology. 2022. PMID: 34662449 Free PMC article. Clinical Trial.
Reply.
Sanyal AJ, Chung C, Myers RP, Bosch J. Sanyal AJ, et al. Among authors: myers rp. Hepatology. 2022 Jul;76(1):E5-E6. doi: 10.1002/hep.32373. Epub 2022 Apr 18. Hepatology. 2022. PMID: 35102590 No abstract available.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, Tsai WW, Mahadevan S, Minto W, Diehl L, Gupta R, Trauner M, Patel K, Noureddin M, Kowdley KV, Gulamhusein A, Bowlus CL, Huss RS, Myers RP, Chung C, Billin AN. Xu J, et al. Among authors: myers rp. Hepatology. 2023 Jan 1;77(1):20-32. doi: 10.1002/hep.32599. Epub 2022 Jul 17. Hepatology. 2023. PMID: 35686937 Free PMC article.
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. Sanyal AJ, et al. Among authors: myers rp. Hepatology. 2019 Dec;70(6):1913-1927. doi: 10.1002/hep.30664. Epub 2019 May 28. Hepatology. 2019. PMID: 30993748
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Alkhouri N, et al. Among authors: myers rp. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. J Hepatol. 2022. PMID: 35439567 Free article. Clinical Trial.
360 results